Department of Biomedical and Neuromotor Science-DIBINEM, 1st Orthopaedic and Traumatologic Clinic, IRCCS Istituto Ortopedico Rizzoli, University of Bologna, Via Giulio Cesare Pupilli 1, 40136 Bologna, Italy.
Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, Via Giulio Cesare Pupilli 1, 40136 Bologna, Italy.
Int J Mol Sci. 2023 Jan 17;24(3):1854. doi: 10.3390/ijms24031854.
Low back pain (LBP) is one of the most common causes of pain and disability. At present, treatment and interventions for acute and chronic low back pain often fail to provide sufficient levels of pain relief, and full functional restoration can be challenging. Considering the significant socio-economic burden and risk-to-benefit ratio of medical and surgical intervention in low back pain patients, the identification of reliable biomarkers such as epigenetic factors associated with low back pain could be useful in clinical practice. The aim of this study was to review the available literature regarding the epigenetic factors associated with low back pain. This review was carried out in accordance with Preferential Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search was carried out in October 2022. Only peer-reviewed articles were considered for inclusion. Fourteen studies were included and showed promising results in terms of reliable markers. Epigenetic markers for LBP have the potential to significantly modify disease management. Most recent evidence suggests that epigenetics is a more promising field for the identification of factors associated with LBP, offering a rationale for further investigation in this field with the long-term goal of finding epigenetic biomarkers that could constitute biological targets for disease management and treatment.
下背痛(LBP)是疼痛和残疾最常见的原因之一。目前,急性和慢性下背痛的治疗和干预往往无法提供足够水平的疼痛缓解,完全恢复功能具有挑战性。考虑到下背痛患者的医疗和手术干预的重大社会经济负担和风险效益比,确定与下背痛相关的可靠生物标志物(如表观遗传因素)可能在临床实践中有用。本研究旨在回顾与下背痛相关的表观遗传因素的现有文献。本综述符合系统评价和荟萃分析的首选报告项目(PRISMA)指南。检索于 2022 年 10 月进行。仅考虑纳入同行评审的文章。纳入了 14 项研究,在可靠标志物方面显示出有希望的结果。LBP 的表观遗传标志物有可能显著改变疾病管理。最近的证据表明,表观遗传学是确定与 LBP 相关因素的更有前途的领域,这为该领域的进一步研究提供了依据,长期目标是找到可能成为疾病管理和治疗生物靶点的表观遗传生物标志物。